ARCHIVES

FDA to refer false statements by regulated companies to SEC.

This article is from The Cancer Letter archive.

Vol. 30 No. 09 | February 27, 2004

Download PDF Visit The Full Archive

Related Articles

Capitol Hill: Trial Results Represent Culmination of Research, Klausner Tells House

March 19, 1999

Sen. Arlen Specter Remembered as Champion Of Federal Biomedical Resesarch Funding

October 19, 2012

20% of Women Do Not Believe Tailored Risk Assessments

August 30, 2013

Deborah Mayer Appointed To NCAB; Cancer Panel Plans Meetings For July 9

May 10, 1991

A. Lindo Patterson: Pioneer and Mentor

October 26, 2021

Paul Goss, Patricia Ganz Discuss Breast Cancer Prevention Trials.

April 20, 2007